《新股消息》和鉑醫藥-B(02142.HK)下周一起招股 入場費約13,050元
和鉑醫藥-B(02142.HK)公布招股詳情,將於下周一(30日)起至下周四(12月3日)招股,計劃發行約1.38億股,當中10%為本地公開發售,其餘90%為國際配售,設15%超額配股權。招股價介乎每股11.7至12.92元,集資最多逾17.85億元,每手1,000股入場費約13,050.19元,預期12月10日掛牌上市,由摩根士丹利、美國銀行及中信證券擔任聯席保薦人。
是次招股將引入9個基石投資者,合共認購約9,200萬美元等值股份,其中Black Rock Funds投資3,000萬美元,HBM Health、高瓴資本、Hudson Bay Capital及Octagon Investments各投資1,000萬美元,安瀾資本投資700萬美元,以及3W、奧博資本與君聯資本分別認購500萬美元等值股份。
以招股價中位數每股12.31元計,所得款項淨額約為15.89億元,約37%將用於研發核心產品HBM9161及HBM9036;約23%用於開發支柱資產HBM4003、註冊備案及潛在商業化;約15%用於其他候選藥物的研發;約12%用於和鉑抗體平台產生的創新型分子發現及合作項目;約5%用以改進平台技術;餘下約8%為一般營運資金。
首席商務官廖邁菁表示,公司目前主要委託CMO生產旗下的產品,中長期會積極考慮在中國建設生物製劑生產設施,屆時將考慮產品需求、地方政府支持政策等去選址,未有透露時間表及預期投資規模。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.